Inhibitor Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
4830 W. KENNEDY BLVD., TAMPA, FL, 33609
Mailing Address
4830 W. KENNEDY BLVD., TAMPA, FL, 33609
Phone
(813) 766-2462
Fiscal Year End
1231
EIN
541641133
Financial Overview
FY2025
$5.69M
Total Assets
$5.28M
Stockholders' Equity
$5.61M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | April 1, 2026 | View on SEC |
| 8-K Current report of material events | April 1, 2026 | View on SEC |
| 10-K Annual financial report | March 26, 2026 | View on SEC |
| 8-K Current report of material events | February 24, 2026 | View on SEC |
| 10-Q Quarterly financial report | November 13, 2025 | View on SEC |
| 8-K Current report of material events | October 27, 2025 | View on SEC |
| 10-Q Quarterly financial report | August 13, 2025 | View on SEC |
| 10-Q Quarterly financial report | May 14, 2025 | View on SEC |
| 4 Insider stock transaction report | April 10, 2025 | View on SEC |
| 4 Insider stock transaction report | April 7, 2025 | View on SEC |
Annual Reports
10-K
March 26, 2026
- Developing a systemic treatment for BCCNS (Gorlin Syndrome) to replace frequent surgeries.
- Partnered with Avior for 'Micro-ITRA' formulation, extending patent protection through 2040.
Material Events
8-K
Legal Issue
April 1, 2026
High Impact
- Company is pursuing legal action to recover $3 million in promised funding
- Active pursuit of legal remedies to enforce contract terms
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.